BioGaia’s Board of Directors has decided to appoint Axel Sjöblad as the new
Managing Director of BioGaia AB. Peter Rothschild has been appointed as Group
President.
It is with satisfaction that BioGaia announces this change, which will enable
the company to increase its focus on sales and marketing while at the same time
realising the major development potential that the Board sees for the Group.
Axel Sjöblad, who is currently Managing Director of Getinge Sverige AB and VP
North and Central Europe and was previously Regional VP Northern European
Markets at Gambro Lundia AB, will assume duties as Managing Director of BioGaia
AB by 1 March 2016 at the latest. His extensive experience in marketing and
sales makes him ideally suited to take over management of the company’s
operations, initially with a special focus on marketing and sales.
In the capacity of Group President, Peter Rothschild will retain overall
responsibility for the BioGaia Group’s research and development activities and
will serve as working Chairman of the group companies TwoPac (BioGaia’s
production company), IBT (BioGaia’s venture to develop a drug for premature
newborns), and CapAble (BioGaia’s venture in innovative delivery systems). He
will also support the development of BioGaia Japan. Furthermore, Peter
Rothschild will continue as Chairman of Metabogen (BioGaia’s investment in
development of microbiome-based products and concepts).
Through this organisational change, BioGaia will be able to reinforce its sales
capabilities and the geographic expansion of its business. At the same time, it
will enable the company to increase the focus on its subsidiaries and associated
companies, as well as the major development potential that the Board sees for
the Group.
”Axel Sjöblad has extensive experience of and an impressive track record in the
healthcare and life sciences area through his earlier positions in the Gambro
and Getinge groups. The Board is confident that Axel Sjöblad is well suited to
take over as Managing Director of BioGaia’s business, which Peter Rothschild has
so brilliantly built up during his time at the helm. We are delighted that Peter
Rothschild will continue in a key position for the company’s development,” says
David Dangoor, Board Chairman.
Peter Rothschild, who founded the company in 1990 together with Jan Annwall, has
guided BioGaia’s establishment and successful development as Managing Director
of BioGaia for 19 years, of which 17 years on the stock exchange. In his active
role as Group President, Peter Rothschild will continue to lead the Group’s
promising strategic development.
Latest press releases from BioGaia
2015-10-12 BioGaia’s probiotic shown to promote growth and prevent recurrent
diarrhoea
2015-09-07 BioGaia to invest further in Infant Bacterial Therapeutics AB
2015-08-18 BioGaia AB – Interim report 1 January – 30 June 2015
BioGaia has published this information in accordance with the Swedish Securities
Act. The information was issued for publication on 20 October 2015, 8:45 a.m.
For additional information please contact
David Dangoor, Chairman: +1 (212) 888 3300
Peter Rothschild, President, BioGaia: +46 8 555 293 00
BioGaia is a healthcare company that develops, markets and sells probiotic
products with documented health benefits. The products are primarily based on
the lactic acid bacterium Lactobacillus reuteri, which has probiotic, health
-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted
on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com
